One-Year,Multicenter,Open-Label,Single-Arm Study Evaluating the Safety and Effectiveness of Etanercept for the Treatment of Moderate-to-Severe Plaque Psoriasis in a Canadian Population

Abstract

French

Background:

Although etanercept is well tolerated and effective in moderate-to-severe plaque psoriasis, data are limited in Canadian practice settings.

Objective:

To assess the effectiveness and safety of etanercept in Canadian patients with moderate-to-severe plaque psoriasis (Physician Global Assessment [PGA] ≥ 3) in routine practice.

Methods:

A 1-year, multicenter, open-label trial of 246 patients enrolled from March 2006 to July 2009 was conducted. Patients received etanercept 50 mg subcutaneously twice weekly for 3 months and then 50 mg once weekly for 9 months. The primary end point was the proportion of patients achieving a PGA score ≤ 2 at month 12. Secondary end points included the proportion of patients achieving PGA score ≤ 2 at months 3, 6, and 9 and change from baseline at month 12 for Patient Global Assessment (PtGA), body surface area, and Dermatology Life Quality Index (DLQI). Adverse events were reported.

Results:

At month 12, 73.5% (95% CI 67.2–79.1) achieved a PGA score ≤ 2. The response was similar regardless of the previous response to systemic or phototherapy. The proportion of patients achieving this score improved from 2.2% (95% CI 0.3–4.2) at baseline to 73.5% (95% CI 67.2–79.1) at 12 months. At 12 months, patients with a DLQI score of 0 or ≥ 5-point improvement was 28.8% (95% CI 22.9–34.7) and 47.3% (95% CI 40.8–53.9), respectively. No new safety signals were reported.

Conclusion:

The majority of this Canadian population demonstrated a meaningful improvement in PGA and DLQI scores over 1 year.

Get full access to this article

View all access options for this article.

References

Bonifati

Carducci

Cordiali

. Correlated increases of tumour necrosis factor-alpha, interleukin-6 and granulocyte monocyte-colony stimulating factor levels in suction blister fluids and sera of psoriatic patients—relationships with disease severity. Clin Exp Dermatol 1994;19:383–7, doi:10.1111/j.1365-2230.1994.tb02687.x.

Ettehadi

Greaves

Wallach

. Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin Exp Immunol 1994;96:146–51, doi:10.1111/j.1365-2249.1994.tb06244.x.

Ameglio

Bonifati

Pietravalle

Fazio

. Interleukin-6 and tumour necrosis factor levels decrease in the suction blister fluids of psoriatic patients during effective therapy. Dermatology 1994; 189:359–63, doi:10.1159/000246879.

Enbrel® (etanercept) [product monograph]. Mississauga (ON): Amgen Canada; 2010.

Elewski

Leonardi

Gottlieb

. Comparison of clinical and pharmacokinetic profiles of etanercept 25 mg twice weekly and 50 mg once weekly in patients with psoriasis. Br J Dermatol 2007;156:138–42, doi:10.1111/j.1365-2133.2006.07585.x.

Feldman

Kimball

Krueger

. Etanercept improves the health-related quality of life of patients with psoriasis: Results of a phase III randomized clinical trial. J Am Acad Dermatol 2005;53: 887–9, doi:10.1016/j.jaad.2005.06.053.

Gelfand

Kimball

Mostow

. Patient-reported outcomes and healthcare resource utilization in patients with psoriasis treated with etanercept: Continuous versus interrupted treatment. Value Health 2008;11:400–7, doi:10.1111/j.1524-4733.2007.00251.x.

Gottlieb

Matheson

Lowe

. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003;139: 1627–32, doi:10.1001/archderm.139.12.1627.

Krueger

Langley

Finlay

. Patient-reported outcomes of psoriasis improvement with etanercept therapy: Results of a randomized phase III trial. Br J Dermatol 2005;153: 1192–9, doi:10.1111/j.1365-2133.2005.06948.x.

10.

Leonardi

Strober

Gottlieb

. Long-term safety and efficacy of etanercept in patients with psoriasis: An open-label study. J Drugs Dermatol 2010;9:928–37.

11.

Leonardi

Powers

Matheson

. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003;349: 2014–22, doi:10.1056/NEJMoa030409.

12.

Moore

Gordon

Kang

. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. J Am Acad Dermatol 2007;56:598–603, doi:10.1016/j.jaad.2006.09.002.

13.

Papp

Tyring

Lahfa

. A global phase III randomized controlled trial of etanercept in psoriasis: Safety, efficacy, and effect of dose reduction. Br J Dermatol 2005;152:1304–212, doi:10.1111/j.1365-2133.2005.06688.x.

14.

Papp

Poulin

Bissonnette

. Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population. J Am Acad Dermatol 2012;66: e33–45, doi:10.1016/j.jaad.2010.07.026.

15.

Tyring

Gottlieb

Papp

. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: Double-blind placebo-controlled randomised phase III trial. Lancet 2006;367: 29–35, doi:10.1016/S0140-6736(05)67763-X.

16.

Tyring

Gordon

Poulin

. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol 2007;143:719–26, doi:10.1001/archderm.143.6.719.

17.

Finlay

Khan

. Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19:210–6, doi:10.1111/j.1365-2230.1994.tb01167.x.

18.

Khilji

Gonzalez

Finlay

. Clinical meaning of change in Dermatology Life Quality Index scores. Br J Dermatol 2002;147 Suppl 62:25–54.

19.

Feldman

Kimball

Woolley

. Clinically meaningful improvements in health-related quality of life from etanercept therapy for patients with moderate to severe psoriasis. J Am Acad Dermatol 2004;50 Suppl 1:155, doi:10.1016/j.jaad.2003.10.543.